IP Library Granted Patent US 10,982,285
Granted Patent B2
US 10,982,285 · App. 15/344,222 · Granted Apr 20, 2021

Biomarkers for the identification of prostate cancer and methods of use

Inventors: Jennifer Freedman (Durham, NC); Yanru Wang (Durham, NC); Hongliang Liu (Durham, NC); Qingyi Wei (Durham, NC); Daniel George (Durham, NC); Steven Patierno (Durham, NC); Bi-Dar Wang (Potomac, MD); Norman Lee (Dayton, MD)
Assignees: DUKE UNIVERSITY; THE GEORGE WASHINGTON UNIVERSITY
C12Q1/6886A61K38/22C12Q2600/106C12Q2600/118C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,982,285
App. No.
15/344,222
Granted
Apr 20, 2021
Kind
B2
Abstract

The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of African American males or non-Hispanic white males.

Claims (16)

1. A method for treating a subject suspected of having an aggressive prostate cancer, the method comprising:

(i) obtaining a blood sample from a subject having prostate cancer;

(ii) isolating genomic DNA from the sample;

(iii) detecting the presence of a C allele at the rs2248490 SNP and a G allele at the rs15736 SNP in the WDR4 gene in the sample, wherein the presence of a C allele at the rs2248490 SNP and a G allele at the rs15736 SNP is associated with aggressive prostate cancer, and;

(iv) administering to the subject at least one cancer therapy for the treatment of prostate cancer.

2. The method of claim 1 , wherein the method further comprises:

(v) detecting -the allele present at at least one additional SNP in a gene, wherein the at least one additional SNP is rs362708 in the RELN gene.

3. The method of claim 2 , wherein the method step of (v) further comprises detecting the allele present at rs3817552 or rs764291 in the MYBPC1 gene.

4. The method of claim 3 , wherein the method of step (v) further comprises detecting the allele present at rs8546 in the NCOR2 gene.

5. The method of claim 1 , wherein the subject is African American.

6. The method of claim 1 , wherein the cancer therapy is selected from the group consisting of chemotherapy, hormone therapy, androgen therapy, radiation, surgery, vaccine therapy, immunotherapy and combinations thereof.

7. The method of claim 4 , wherein the method step of (iii) further comprises detecting the allele present at rs11911090 in the WDR4 gene.

8. The method of claim 1 , wherein the method step of (iii) comprises detecting the allele present of a SNP at rs3817552 or rs764291 in the MYBPC1 gene.

9. The method of claim 1 , wherein the method step of (iii) further comprises detecting the allele present at rs8546 in the NCOR2 gene.

10. The method of claim 1 , wherein the method step of (iii) further comprises detecting the allele present at rs3817552 in the MYBPC1 gene.

11. The method of claim 1 , wherein the method step of (iii) further comprises detecting the allele present at rs11911090 in the WDR4 gene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2017
From: FREEDMAN, JENNIFER; WANG, YANRU; LIU, HONGLIANG; WEI, QINGYI; GEORGE, DANIEL; PATIERNO, STEVEN
To: DUKE UNIVERSITY
Reel/Frame 041463/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2017
From: WANG, BI-DAR; LEE, NORMAN
To: THE GEORGE WASHINGTON UNIVERSITY
Reel/Frame 041463/0778 →
Continuity (3)
Provisional Application 62250723 · Nov 4, 2015
Provisional Application 62393293 · Sep 12, 2016
Related Publication 20170166977A1 · Jun 15, 2017